Post-Transplant TKI Salvage Therapy Provides Significant Survival Benefit Following Relapse in CML by HMP Global

BTK Inhibitors Important in the Treatment Landscape of MCL by HMP Global

In an interview with Oncology Learning Network, Randall A. Oyer, MD, Association of Community Cancer Centers (ACCC) President, discusses the basis and goal of his presidency theme, entitled “Community Oncology Can Close the Gap in Cancer Research.”

Direct-to-Patient Strategies in Multiple Myeloma Care by HMP Global

In an interview with Oncology Learning Network, Kevin Kalinsky, MD, MS, Herbert Irving Associate Professor of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, discussed why gene profiling plays such an important role in the management of patients with early-stage breast cancer.

Non-Chemotherapy Approach Induces High Rate of Undetectable MRD in CLL by HMP Global

KTE-X19 Shows Great Efficacy in Heavily Pretreated MCL by HMP Global

Joel Randolph Hecht, MD, David Geffen School of Medicine, University of California Los Angeles, shares findings from the SEQUOIA clinical trial of GEM-refractory pancreatic adenocarcinoma, an overview of recent studies and therapy options for metastatic pancreatic cancer, and what he believes may be the way forward to improve treatment outcomes in this patient population.

Matt Kalaycio, MD, Discusses the Historical Treatment of CML by HMP Global

Belantamab Mafodotin Demonstrates Promising Safety and Efficacy for MM by HMP Global